0	DDI-false	Other Potentially Important Drug Interactions: @DRUG$: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, @DRUG$, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
1	DDI-false	"Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;@DRUG$;halothane;certain antibiotics, especially the @DRUG$ and polymyxins;lithium;magnesium salts;procainamide;and quinidine."
2	DDI-false	Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as @DRUG$, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, @DRUG$, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
3	DDI-effect	Selegiline - @DRUG$ and the selective MAO inhibitor @DRUG$ may have synergistic antidepressant activity if used concomitantly.
4	DDI-false	Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.
5	DDI-false	Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, @DRUG$, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
6	DDI-false	@DRUG$, another @DRUG$, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.
7	DDI-false	Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, @DRUG$, valsartan, metformin and amlodipine did not result in clinically significant increases in @DRUG$ exposure.
8	DDI-false	These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
9	DDI-false	In the first double-blind comparative study (28-week) of @DRUG$ and risperidone, olanzapine 10 to 20 mg/day proved to be significantly more effective than @DRUG$ 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms.
10	DDI-false	- @DRUG$ and colestipol @DRUG$: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract
11	DDI-advise	The potential effects of increased plasma concentrations of @DRUG$ or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with @DRUG$.
12	DDI-effect	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
13	DDI-int	@DRUG$ may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., @DRUG$ and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
14	DDI-advise	Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving @DRUG$ with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, @DRUG$, and beta-blockers.)
15	DDI-mechanism	Coadministration of @DRUG$ and cyclosporine, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.
16	DDI-effect	Diuretics: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.
17	DDI-effect	Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE inhibitors, including @DRUG$.
18	DDI-effect	The concomitant administration of @DRUG$ and other @DRUG$ have resulted in previous reports of rhabdomyolysis.
19	DDI-mechanism	Ingestion of @DRUG$ may increase serum concentrations of digoxin and @DRUG$ and increase cyclosporine s nephrotoxicity.
20	DDI-advise	@DRUG$ should not be administered during @DRUG$ treatment.
21	DDI-advise	If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.
22	DDI-effect	When a @DRUG$ is added to the therapy of a patient receiving @DRUG$, an additional antihypertensive effect is usually observed.
23	DDI-advise	Care should be taken if @DRUG$ is used concomitantly with @DRUG$s of the verapamil type.
24	DDI-mechanism	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.
25	DDI-mechanism	Caffeine Theobromine @DRUG$, like other quinolones, may inhibit the metabolism of caffeine and @DRUG$.
26	DDI-mechanism	Digoxin: Digoxin concentrations are increased by about 15% when @DRUG$ and @DRUG$ are administered concomitantly.
27	DDI-effect	@DRUG$ may exacerbate the rebound hypertension which can follow the withdrawal of @DRUG$.
28	DDI-effect	Combinations of @DRUG$ and @DRUG$ were indifferent for 16 and synergistic for 11 of the resistant strains.
29	DDI-mechanism	"Ascorbic acid: Doses of ascorbic acid (@DRUG$) 1 g/day have been reported to increase plasma concentration of @DRUG$ by ~47%, possibly by inhibiting conjugation;"
30	DDI-mechanism	Coadministration of @DRUG$ and @DRUG$ as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.
31	DDI-mechanism	Amitriptyline: Concurrent administration of 25 mg or 100 mg @DRUG$ with 50 mg @DRUG$ increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
32	DDI-effect	However, because bleeding has been reported when @DRUG$ and other nonsteroidal anti-inflammatory agents have been administered to patients on @DRUG$, the physician should be cautious when administering ibuprofen to patients on anticoagulants.
33	DDI-effect	@DRUG$: May decrease @DRUG$ anti-inflammatory action by competing for the same receptors.
34	DDI-mechanism	However, the peak plasma level of metformin was reduced by approximately 20% when taking @DRUG$ due to a slight delay in the absorption of @DRUG$.
35	DDI-mechanism	Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant @DRUG$ administration may result in an increase in @DRUG$ plasma levels.
36	DDI-advise	Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, @DRUG$, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
37	DDI-advise	Refer to the package insert for @DRUG$ preparations before use of such preparations with @DRUG$
38	DDI-advise	Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.
39	DDI-int	@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, @DRUG$, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
40	DDI-int	@DRUG$ may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, @DRUG$, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
41	DDI-advise	@DRUG$ should not be administered concomitantly with other sympathomimetic drugs (such as @DRUG$) because of possible additive effects and increased toxicity.
42	DDI-advise	Caution should be used when administering or taking @DRUG$ with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, @DRUG$, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
43	DDI-int	Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.
44	DDI-int	@DRUG$ may interact with @DRUG$, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
45	DDI-int	@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, @DRUG$, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
46	DDI-int	Therefore, @DRUG$ has the potential for interaction with adrenergic and @DRUG$.
47	DDI-int	Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between @DRUG$ and @DRUG$, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.
48	DDI-int	@DRUG$ may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, @DRUG$ (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
49	DDI-int	A possible interaction between @DRUG$ and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.
